Baseline and clinical characteristics of invasively ventilated COVID-19 survivors (n=50)
| Baseline characteristics | |
| Age years | 61 (52–68) |
| Sex, male | 26 (52) |
| BMI kg·m−2 | 28 (27–34) |
| BMI group | |
| Normal (18.5–24.9 kg·m−2) | 5 (10) |
| Overweight (25–29.9 kg·m−2) | 26 (52) |
| Obese (>30 kg·m−2) | 19 (38) |
| Comorbidities | |
| Hypertension | 21 (42) |
| Dyslipidaemia | 14 (28) |
| Diabetes mellitus | 12 (24) |
| COPD | 4 (8) |
| Asthma | 3 (6) |
| Active malignancy | 3 (6) |
| SAHS | 3 (6) |
| Ischaemic heart disease | 1 (2) |
| Chronic renal disease | 1 (2) |
| Smoking history | |
| Never | 33 (66) |
| Former | 10 (20) |
| Current | 2 (4) |
| Unknown | 5 (10) |
| Charlson Comorbidity Index | 2 (1–4) |
| Clinical characteristics | |
| SOFA | 6.5 (4.5–7) |
| Invasive mechanical ventilation days | 11 (8–22) |
| Prolonged mechanical ventilation (≥21 days) | 13 (26) |
| Tracheostomy | 11 (22) |
| Re-intubation | 6 (12) |
| Pulmonary thromboembolism | 9 (18) |
| Continuous neuromuscular blockade | 46 (92) |
| Systemic corticosteroids during admission# | 50 (100) |
| Length of stay in ICU days | 15 (12–29) |
| Length of stay post-ICU days | 7.5 (6–13) |
| Length of stay in hospital days | 27.5 (23–45) |
| Supplemental O2 | |
| Hospital discharge | 27 (54) |
| 3 months follow-up visit | 3 (6) |
| 6 months follow-up visit | 2 (4) |
| Hospital discharge destination | |
| Home | 20 (40) |
| Home with follow-up physiotherapy | 15 (30) |
| Inpatient rehabilitation | 13 (26) |
| Home with outpatient physiotherapy | 2 (4) |
Data are presented as median (25th–75th percentile) for continuous variables and n (%) for categorical variables. BMI: body mass index; SAHS: sleep apnoea–hypopnoea syndrome; SOFA: sequential organ failure assessment; ICU: intensive care unit. #: course of intravenous dexamethasone.